A
Azafaros
Develops new therapeutic agents for the treatment of rare metabolic disorders
About Azafaros
Azafaros is a biopharmaceutical company dedicated to developing innovative therapies for severe rare metabolic disorders, particularly neurogenetic diseases. The company operates in the rare disease market, targeting conditions that have limited treatment options. Azafaros' business model revolves around drug discovery and development, with a focus on advancing its clinical candidate, AZ 3102, an orally available azasugar designed to treat the central nervous system and interfere with the metabolism of glycosphingolipids. This candidate is currently in the clinical stage and aims to modify disease pathways through a unique dual mode of action. The company generates revenue through partnerships, investments, and potential future sales of its therapeutic products. Azafaros is backed by a syndicate of leading Dutch and Swiss investors, including Forbion, BioGeneration Ventures, BioMedPartners, and Schroder Adveq. The company leverages the expertise of its team and partners in orphan drug development to expand its product pipeline and bring new treatment options to patients with rare metabolic diseases.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- Leiden, Netherlands
- Employees
- 31
- Open positions
- None listed
- Dealroom signal
- 90.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Disease, Metabolism, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Azafaros.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | May 2025 | $145M | $581M | BioGeneration Ventures · Forbion Capital Partners · Pictet · Seroba Life Sciences | ↗ |
| SERIES AOther financing | Feb 2020 | $28M | $110M | Forbion Capital Partners · BioGeneration Ventures · BioMedVC | ↗ |
Growth signals
Latest recorded traffic for Azafaros is 3K monthly website visits, up 36.4% over the last three months. Azafaros's team grew 14.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series A6 investors entered at this stage
Forbion Capital Partners
BioMedVC
Jeito Capital
Pictet
Seroba Life Sciences
Schroders Capital
Other known investors4 additional known investors
Amsterdam UMC
Leiden University
University of Amsterdam
VU Amsterdam
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Azafaros on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Azafaros’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.